Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of September 30, 2013 will be sufficient to fund its currently planned operations into 2015 and through the expected release of final survival results from both the Synergy and Borealis-1 trials. The cash burn is expected to be reduced in 2014 compared with 2013 because the company-sponsored Borealis-1 trial is expected to incur the majority of its costs in 2013.  Further, the investigator-sponsored OGX-427 Phase 2 trials are substantially less capital-intensive than company-sponsored trials. 
  • At November 7, 2013, The Company had 14,707,636 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012Collaboration revenue$
    9,862$
    ,570$
    21,278$
    ,315Operating expenses:  Research and development18,00412,89542,12224,303  General and administrative2,4731,9657,4465,749Total operating expenses20,47714,86049,56830,052Loss from operations(10,615)(8,290)(28,290)(19,737)  Other income5612,3703,1192,742Net loss$
    (10,054)$
    (5,920)$
    (25,171)$
    (16,995)Basic and diluted net loss per share$
    (0.68)$
    (0.40)$
    (1.72)$
    (1.29)Weighted average number of basic and diluted common shares14,690,98414,619,84214,675,24413,141,940Consolidated Balance Sheets(In thousands) September 30,  December 31, 20132012 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    47,091$
    75,697  Interest receivable295327  Amounts receivable9,922714  Prepaid expenses and other current assets2,7133,755  Property, equipment and other assets1,6181,523Total assets$
    ,639$
    82,016Liabilities and stockholder
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
    (Date:3/4/2015)... 04, 2015 Follow us on ... of the fastest growing technologies in the life sciences ... visualization is driving growth in nucleic acid detection technologies ... of gene expressions will continue to benefit the qPCR ... fields ranging from pharma, biotech, food & beverage to ...
    (Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
    (Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
    Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
    ... N.Y., Jan. 28 XTL Biopharmaceuticals Ltd. (Nasdaq: ... January 27, 2009 it received a Staff Determination Letter ... the Company that the staff of Nasdaq,s Listing Qualifications ... Rule 4300, that the Company,s American Depository Shares ("ADRs") ...
    ... Binding Site Limited,("The Binding Site" or the "Company"), ... publication of the first,international guidelines recommending first-line use ... myeloma, a cancer of cells in the bone,marrow, ... The guidelines were written on behalf ...
    ... Business Development , ... Olyphant, PA (PRWEB) January 28, 2009 -- ... the hiring of Mr. Terry Ladd as Vice President of Business Development. ... Director, Business Development and Marketing., , , , ,Mr. Ladd will be ...
    Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7Calvert Labs Announces the Hiring of Terry Ladd 2
    (Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
    (Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
    (Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
    Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
    ... in Munich, Germany and Ann Arbor, Michigan released today ... National Institute on Aging, National Institutes of Health, Baltimore, ... cells. , In their work they first identified and ... methods. Then they employed extensive DNA promoter analysis based ...
    ... Throughout the world, amateurs, experts and the media agree ... that the bodys own opioids, so called endorphins, are ... never been proved until now. Researchers at the Technische ... demonstrate the existence of an endorphin driven runners high. ...
    ... ... Entry, WASHINGTON, Feb. ... Department of Homeland Security (DHS) is,expanding the operation of their successful biometrics-at-sea ... securing the more than 95,000 miles of,America,s coastline," said Rear Adm. Wayne ...
    Cached Biology News:The myth of runner's high revisited with brain imaging 2The myth of runner's high revisited with brain imaging 3DHS Expands Biometrics-at-Sea Program to the Florida Straits 2
    Alkaline Phosphatase Stabilizer Solution, 1 L...
    The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
    DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
    ... Our fastest automated perfusion system. ... in perfusion, physiology, biophysics, electrochemistry, or ... reproducibility with 1.5-4 millisecond accuracy ... Microprocessor-based for accuracy and flexibility ...
    Biology Products: